Skip to main content
Erschienen in: Endocrine 2/2018

01.03.2018 | Editorial

Predicting an adrenal crisis: can we do it?

verfasst von: Ashley Grossman

Erschienen in: Endocrine | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Excerpt

Primary adrenal failure is a condition which should be readily treated with a normal quality of life: we have long been aware of the basic pathophysiology. We are able to essentially fabricate the deficient hormones, and we have sophisticated assays to assess replacement adequacy. Nevertheless, normalisation of the quality of life, avoidance of adrenal crises, and attainment of a normal mortality, appear to be difficult goals to achieve [1]. As clinicians, we weave between the Scylla of under-treatment with consequent fatigue and general ill-health, and the ever-present risk of adrenal crises, as opposed to the Charybdis of over-treatment and the metabolic syndrome. Indeed, even in a highly experienced unit with skilled staff and good patient training, the risk of adrenal crises seems to be ever present [2]. Such patient training includes warnings of ‘sick day’ rules, emergency injection packs, and in some cases specific patient training days or evenings. It is important to know that subcutaneous injection can be virtually as effective as the standard suggestion of intramuscular hydrocortisone [3], although it should still be emphasised that the advice to ‘double the oral dose’ during febrile illnesses has hardly any firm evidence base. Nevertheless, in spite of all this activity, adrenal crises and their consequent morbidity and indeed mortality remain stubbornly present concerns in our patients’ lives. …
Literatur
1.
Zurück zum Zitat A. Grossman, G. Johannsson, M. Quinkler, P. Zelissen, Perspectives on the management of adrenal insufficiency: Clinical insights from across Europe. Eur. J. Endocrinol. 169, R165–R175 (2013)CrossRefPubMedPubMedCentral A. Grossman, G. Johannsson, M. Quinkler, P. Zelissen, Perspectives on the management of adrenal insufficiency: Clinical insights from across Europe. Eur. J. Endocrinol. 169, R165–R175 (2013)CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat S. Hahner, C. Spinnler, M. Fassnacht et al., High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J. Clin. Endocrinol. Metab. 100, 407–416 (2015)CrossRefPubMed S. Hahner, C. Spinnler, M. Fassnacht et al., High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J. Clin. Endocrinol. Metab. 100, 407–416 (2015)CrossRefPubMed
3.
Zurück zum Zitat S. Hahner, S. Burger-Stritt, B. Allolio: Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur. J. Endocrinol. 169, 147–154 (2013) S. Hahner, S. Burger-Stritt, B. Allolio: Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur. J. Endocrinol. 169, 147–154 (2013)
5.
Zurück zum Zitat A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli et al., Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. [Epub ahead of print] (2017) A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli et al., Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. [Epub ahead of print] (2017)
6.
Zurück zum Zitat D.J.F. Smith, H. Prabhudev, S. Choudhury, K. Meeran, Prednisolone has the same cardiovascular risk profile as hydrocortisone in glucocorticoid replacement. Endocr. Connect 68, 766–772 (2017)CrossRef D.J.F. Smith, H. Prabhudev, S. Choudhury, K. Meeran, Prednisolone has the same cardiovascular risk profile as hydrocortisone in glucocorticoid replacement. Endocr. Connect 68, 766–772 (2017)CrossRef
Metadaten
Titel
Predicting an adrenal crisis: can we do it?
verfasst von
Ashley Grossman
Publikationsdatum
01.03.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1567-7

Weitere Artikel der Ausgabe 2/2018

Endocrine 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.